Journal of Biomedical Sciences
Research Article Peer-review, Open Access

Nonspecific and Specific Biochemical Markers in the Precipitating Waters of Covid-19-Overexpressing Pregnant Women

Nozimova N. H. [1]

Narzullayeva M. H. [2]

Abstract

The COVID-19 pandemic has posed considerable hurdles to healthcare systems, especially in the management of pregnant women. This study examines the changes in nonspecific and specific biochemical markers in pregnant women impacted by COVID-19. Nonspecific markers, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), as well as specific markers such as interleukin-6, D-dimer, and ferritin, were assessed for their diagnostic and prognostic relevance. Blood samples from pregnant women, both infected and uninfected with COVID-19, were tested to compare these markers. The findings revealed that nonspecific indicators predominantly signify general inflammatory responses, whereas specific markers represent intricate immunological systems activated by the viral infection. CRP and ESR values were markedly increased in pregnant women with COVID-19, indicating enhanced systemic inflammation. Conversely, certain markers like interleukin-6 and D-dimer were recognized as essential predictors of problems during pregnancy. These findings highlight the unique clinical significance of nonspecific and particular indicators. Nonspecific markers offer a general assessment of infection severity, whereas specific markers facilitate a more profound comprehension of the immune response and its possible effects on pregnancy outcomes. This study underscores the significance of employing these indicators for the effective clinical management of pregnancies afflicted with COVID-19. The integration of generic and specific biochemical indicators into standard diagnostics might facilitate early detection, monitoring, and personalized therapy approaches, thereby enhancing maternal and fetal outcomes. Future research should concentrate on the extensive application of these indicators to alleviate pregnancy-related difficulties linked to COVID-19.

Keywords: COVID-19, pregnancy, nonspecific markers, specific markers, biochemical analysis, immune response.

[1, 2] Tashkent Pediatric Medical Institute

Introduction

The COVID-19 pandemic, induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has significantly affected world health, presenting distinct issues in the management of susceptible populations, especially pregnant women. Pregnancy triggers intricate physiological and immunological changes, rendering pregnant individuals especially vulnerable to problems from infections, such as COVID-19. These modifications may modify inflammatory responses, coagulation pathways, and immunological systems, which are essential in influencing mother and fetal outcomes during infections. Biochemical indicators are essential instruments for evaluating the severity and prognosis of COVID-19. These markers are classified into nonspecific markers, which yield general information regarding systemic inflammation and infection (e.g., C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)), and specific markers, which provide a more focused comprehension of the immune and coagulation responses elicited by SARS-CoV-2 (e.g., interleukin-6, D-dimer, ferritin). Nonspecific markers act as preliminary indicators of inflammatory conditions, but specific markers are essential for detecting consequences such hypercoagulability, cytokine storms, and severe acute respiratory distress. The physiological changes in pregnant women confound the interpretation of these markers, requiring a sophisticated approach to their use in diagnostics and treatment. Current research indicates that increased levels of CRP, ESR, interleukin-6, and D-dimer are frequently detected in COVID-19 patients; however, their clinical significance in pregnancy is yet inadequately investigated. Comprehending the interaction between nonspecific and particular markers in this distinct population is essential for enhancing clinical care, from early detection to complication management. This research examines the dynamics of nonspecific and specific biochemical indicators in pregnant women who are positive for COVID-19. It seeks to clarify their diagnostic and prognostic significance, enhancing comprehension of the disease's biology during pregnancy. Integrating these findings into clinical practice enables healthcare practitioners to improve maternal and fetal outcomes amid COVID-19.

Literature Review

The study of biochemical markers in the context of COVID-19 has gained substantial attention, particularly in vulnerable populations like pregnant women. Biochemical markers are crucial for understanding the disease's impact on inflammation, immune response, and coagulation processes. This section reviews key studies on nonspecific and specific markers relevant to COVID-19 in pregnant women.

Nonspecific markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are widely recognized as indicators of systemic inflammation. Elevated levels of CRP have been consistently associated with COVID-19 severity in the general population and in pregnant women[1]. ESR, another inflammatory marker, has shown similar trends, particularly in cases with cytokine storm or severe inflammation[2]. These markers are useful for tracking the progression of infection but lack specificity for the underlying cause of inflammation.

Specific markers like interleukin-6 (IL-6), D-dimer, and ferritin are directly linked to the pathophysiology of COVID-19. IL-6, a pro-inflammatory cytokine, plays a pivotal role in the cytokine release syndrome observed in severe cases[3]. Studies have demonstrated significantly higher IL-6 levels in pregnant women with COVID-19 compared to healthy controls, correlating with adverse outcomes[4]. D-dimer, a marker of hypercoagulability, is particularly relevant during pregnancy due to the physiological increase in coagulation activity. Elevated D-dimer levels in pregnant women with COVID-19 have been linked to

[1] Ginsburg, K. R., et al. (2021). "CRP as a marker of disease severity in COVID-19-positive pregnant women." Journal of Obstetrics and Gynecology Research, 47(2), 145-152.
[2] Wong, Y. P., et al. (2020). "Role of ESR in monitoring inflammatory response in COVID-19." Clinical Chemistry and Laboratory Medicine, 58(12), 2093-2100.
[3] Chen, G., et al. (2020). "Elevated interleukin-6 and COVID-19 severity." Nature Reviews Immunology, 20(8), 469-478.
[4] Di Toro, F., et al. (2021). "IL-6 as a predictor of pregnancy complications in COVID-19." Reproductive Sciences, 28(1), 146-154.

thrombotic complications, preeclampsia-like syndromes, and adverse fetal outcomes[5]. Ferritin, an acute-phase reactant, serves as a marker of systemic inflammation and iron dysregulation. High ferritin levels have been associated with poor maternal and fetal outcomes in COVID-19-positive pregnancies[6].

The combined analysis of nonspecific and specific markers provides a comprehensive understanding of COVID-19's impact on pregnant women. While nonspecific markers guide general inflammation monitoring, specific markers help predict complications such as coagulopathy, severe hypoxia, and cytokine storms. This dual approach is critical for tailoring treatment strategies and improving clinical outcomes[7].

Methodology

This study employed a cross-sectional observational approach to examine the levels of generic and specific biochemical markers in pregnant women impacted by COVID-19. The main aim was to evaluate and contrast the markers in COVID-19-positive pregnant women with those in healthy pregnant controls to ascertain their diagnostic and prognostic relevance. The research was performed in a tertiary care hospital featuring a specialized obstetric and infectious illness unit. One hundred pregnant women participated in the study. Participants were categorized into two groups: 50 women diagnosed with COVID-19 via reverse transcription-polymerase chain reaction (RT-PCR) testing and 50 healthy pregnant women who tested negative for COVID-19 and exhibited no symptoms of the illness. All individuals were matched based on age, gestational age, and concomitant conditions to reduce potential confounding variables. Women with pre-existing inflammatory illnesses, cancers, or coagulation disorders were excluded to ensure the specificity of the results. Demographic and clinical data were gathered for all participants, encompassing age, gestational age, body mass index, and pertinent medical history. Symptoms associated with COVID-19, including fever, cough, and respiratory distress, were documented alongside obstetric outcomes, such as preterm labor or preeclampsia. Venous blood samples were obtained from all subjects following the acquisition of informed consent. Samples were collected in the morning to mitigate diurnal fluctuations in biomarker levels. Laboratory analyses concentrated on both nonspecific and specific biochemical indicators. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were selected as nonspecific indicators of systemic inflammation. Interleukin-6 (IL-6), D-dimer, and ferritin were chosen as particular biomarkers because of their involvement in inflammatory and coagulation pathways in COVID-19. CRP was quantified using a high-sensitivity immunoassay, whilst ESR was evaluated by the Westergren method. IL-6 concentrations were determined via an enzyme-linked immunosorbent assay (ELISA), while D-dimer levels were assessed using an immunoturbidimetric technique. Serum ferritin concentrations were assessed with a chemiluminescent microparticle immunoassay. All tests were conducted in duplicate to guarantee dependability, accompanied by stringent quality control protocols. Calibration standards were utilized by manufacturer specifications, and laboratory procedures complied with recognized clinical principles. Data analysis was conducted with SPSS (version 25.0). Descriptive statistics, comprising the mean and standard deviation, were computed for each biomarker. Differences between the COVID-19-positive group and the control group were assessed using independent t-tests for normally distributed data and Mann-Whitney U-tests for non-normally distributed data. A p-value below 0.05 was deemed statistically significant. Correlation studies were performed to investigate the links between biochemical indicators and clinical outcomes, including illness severity and pregnancy-related problems. The study received ethical approval from the institutional ethics committee. Informed agreement was obtained from all subjects, and confidentiality was rigorously upheld during the study. Participants received normal clinical

[5] Levi, M., et al. (2021). "COVID-19-related coagulopathy and D-dimer levels in pregnancy." The Lancet Hematology, 8(2), e163-e170.
[6] Zhou, F., et al. (2020). "Ferritin as an inflammatory marker in severe COVID-19 cases." The Lancet Infectious Diseases, 20(6), 758-768.
[7] Gao, Y., et al. (2021). "The interplay of nonspecific and specific markers in COVID-19 management." Frontiers in Medicine, 8, 654759.

treatment, without any supplementary interventions beyond usual diagnostic assessments. Despite being confined to a single location with a modest sample size, the findings are anticipated to yield significant insights into the significance of biochemical markers in the management of COVID-19 during pregnancy. Additional research with bigger and more diverse cohorts is advised to corroborate these findings and enhance the comprehension of COVID-19's effects on maternal and fetal health.

Results and Discussion

The examination of biochemical markers in pregnant women with COVID-19 yielded important insights into the physiological and pathological alterations linked to the infection. The research indicated that nonspecific indicators, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), were markedly increased in pregnant women positive for COVID-19 in comparison to healthy controls. These markers signified increased systemic inflammation, consistent with findings from recent research done between 2022 and 2024. Likewise, particular biomarkers such as interleukin-6 (IL-6), D-dimer, and ferritin exhibited significant elevations, indicating the intricate immunological responses and hypercoagulable conditions linked to COVID-19 in pregnancy. In Uzbekistan, where the healthcare system for pregnancy has encountered difficulties throughout the pandemic, these findings possess significant clinical importance. CRP and ESR, as nonspecific indicators, were effective in the early identification of systemic inflammation, enabling prompt therapies. Nevertheless, particular markers provide enhanced insight into disease mechanisms. Increased IL-6 levels were significantly associated with severe maternal outcomes, such as preeclampsia-like syndromes and premature labor, underscoring their prognostic significance. Increased D-dimer levels signify an elevated risk of thrombotic events, highlighting the importance of monitoring coagulation pathways in pregnant women with COVID-19. The results underscore the necessity of including biochemical marker analysis into routine prenatal care, especially during epidemics of infectious diseases. Uzbekistan's adoption of these approaches can markedly improve maternal and fetal outcomes, considering the nation's continuous endeavors to fortify its healthcare system. The research emphasizes the necessity for a more profound theoretical investigation into the mechanisms underlying the observed alterations in biomarkers. Nonspecific markers offer general insights into systemic inflammation, however, specific markers like IL-6 and ferritin necessitate additional research to elucidate their exact functions in the pathophysiology of COVID-19 and its effects on pregnancy. Knowledge gaps remain about the long-term effects of these biomarker alterations on maternal and newborn health. Current research is confined to the acute periods of infection, leaving unresolved inquiries on the potential developmental and health issues in neonates born to moms who are COVID-19-positive. Furthermore, practical obstacles in resource-constrained environments, such as specific areas in Uzbekistan, underscore the necessity for economical and accessible biomarker testing techniques. Subsequent research should concentrate on longitudinal studies that monitor maternal and newborn outcomes post-delivery. Such investigations would elucidate the long-term ramifications of modified biochemical markers and offer a more thorough comprehension of COVID-19's effects on pregnancy. The creation of prediction models of biomarker data may facilitate clinical decision-making, allowing for tailored care plans for high-risk pregnancies. Future studies should investigate the molecular pathways connecting SARS-CoV-2 infection to changes in biomarkers. Understanding these systems would guide specific therapeutic measures, such as anti-inflammatory or anticoagulant treatments, customized for the distinct requirements of pregnant women. The findings underscore the pressing necessity for capacity enhancement within Uzbekistan's healthcare sector. Training programs for healthcare workers, improvements in laboratory facilities, and public health measures to enhance maternal health during pandemics are essential. Incorporating biomarker-based diagnoses into standard therapy would constitute a substantial advancement in the management of COVID-19 and other infections that threaten pregnant women.

This work enhances the existing knowledge on COVID-19 during pregnancy, emphasizing the significance of biochemical indicators in optimizing clinical outcomes. It establishes a basis for subsequent research and practical improvements in maternal healthcare, both in Uzbekistan and

internationally.

References

1. Ginsburg, K. R., et al. (2021). "CRP as a marker of disease severity in COVID-19-positive pregnant women." Journal of Obstetrics and Gynecology Research, 47(2), 145-152.
2. Wong, Y. P., et al. (2020). "Role of ESR in monitoring inflammatory response in COVID-19." Clinical Chemistry and Laboratory Medicine, 58(12), 2093-2100.
3. Chen, G., et al. (2020). "Elevated interleukin-6 and COVID-19 severity." Nature Reviews Immunology, 20(8), 469-478
4. Di Toro, F., et al. (2021). "IL-6 as a predictor of pregnancy complications in COVID-19." Reproductive Sciences, 28(1), 146-154.
5. Levi, M., et al. (2021). "COVID-19-related coagulopathy and D-dimer levels in pregnancy." The Lancet Hematology, 8(2), e163-e170.
6. Zhou, F., et al. (2020). "Ferritin as an inflammatory marker in severe COVID-19 cases." The Lancet Infectious Diseases, 20(6), 758-768.
7. Gao, Y., et al. (2021). "The interplay of nonspecific and specific markers in COVID-19 management." Frontiers in Medicine, 8, 654759.
8. Huang, C., Wang, Y., Li, X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497-506.
9. Wu, Y., Liu, C., Dong, L., et al. (2020). Coronavirus disease 2019 among pregnant Chinese women: Case series data on the safety of vaginal birth and breastfeeding. BJOG: An International Journal of Obstetrics & Gynaecology, 127(9), 1109-1115.
10. Knight, M., Bunch, K., Vousden, N., et al. (2020). Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in the UK: National population-based cohort study. BMJ, 369, m2107.
11. Zheng, Z., Peng, F., Xu, B., et al. (2020). Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. Journal of Infection, 81(2), e16-e25.
12. Chen, R., Zhang, Y., Huang, L., et al. (2020). Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing cesarean delivery. Frontiers in Medicine, 7, 586980.
13. Alijotas-Reig, J., Esteve-Valverde, E., Ferrer-Oliveras, R., et al. (2020). Immunologic and clinical considerations on SARS-CoV-2 infection in pregnancy. American Journal of Reproductive Immunology, 84(5), e13309.
14. Ahmed, I., Azhar, A., Eltaweel, N., & Tan, B. K. (2020). First COVID-19 maternal mortality in the UK associated with thrombotic complications. British Journal of Haematology, 190(1), e37-e38.
15. Gómez-Chaverri, M., & Arias, M. (2020). Elevated D-dimer levels in a pregnant patient with COVID-19: A case report. Obstetrics & Gynecology Cases - Reviews, 7(6), 174.
16. Wastnedge, E. A. N., Reynolds, R. M., van Boeckel, S. R., et al. (2021). Pregnancy and COVID-19. Physiological Reviews, 101(1), 303-318.
17. Huntley, B. J. F., Huntley, E. S., Di Mascio, D., et al. (2020). Rates of maternal and perinatal mortality and vertical transmission in pregnancies complicated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Obstetrics & Gynecology, 136(2), 303-312.
18. Abeysekera, W. M., Premaratne, P. A., & Gunasekara, S. (2021). Maternal IL-6 levels during COVID-19 infection and its impact on pregnancy outcomes: A systematic review. Journal of

Maternal-Fetal & Neonatal Medicine, 34(21), 3487-3495.

19. Vintejoux, M., Nguyen, L. S., Malhaire, C., et al. (2021). Ferritin and IL-6 levels in COVID-19-positive pregnant women: A retrospective study. Journal of Infection and Public Health, 14(10), 1508-1512.
20. Hsu, A. L., Guan, M., Johannesen, E., et al. (2021). COVID-19 in pregnancy: A review of maternal and fetal biomarkers. Clinical Obstetrics and Gynecology, 64(1), 134-142.
21. Yu, N., Li, W., Kang, Q., et al. (2020). Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan: A retrospective, single-centre, descriptive study. The Lancet Infectious Diseases, 20(5), 559-564.
22. Li, M., Chen, L., Zhang, J., et al. (2020). The predictive value of interleukin-6 for COVID-19 severity and mortality in infected pregnant women. Journal of Clinical Laboratory Analysis, 34(10), e23428.